Reuters: Health
Swiss drugmaker Roche is paying up to $1.4 billion to buy U.S. biotech company Promedior, whose main drug candidate against the lung disease idiopathic pulmonary fibrosis is set to begin late-stage trials, Promedior said on Friday.
Roche buys U.S. drugmaker Promedior for up to $1.4 billion to get lung drug
Roche buys U.S. drugmaker Promedior for up to $1.4 billion to get lung drug
Reuters: Health
Swiss drugmaker Roche is paying up to $1.4 billion to buy U.S. biotech company Promedior, whose main drug candidate against the lung disease idiopathic pulmonary fibrosis is set to begin late-stage trials, Promedior said on Friday.
Reuters: Health
Swiss drugmaker Roche is paying up to $1.4 billion to buy U.S. biotech company Promedior, whose main drug candidate against the lung disease idiopathic pulmonary fibrosis is set to begin late-stage trials, Promedior said on Friday.
GSK sees breakthrough in shingles vaccine output in 2024
GSK sees breakthrough in shingles vaccine output in 2024
Reuters: Health
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production. 
Reuters: Health
GlaxoSmithKline said further growth from its shingles vaccine, which has boosted earnings, would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.
ResTORbio stops testing lead drug for respiratory illness; shares plummet
ResTORbio stops testing lead drug for respiratory illness; shares plummet
Reuters: Health
ResTORbio Inc said on Friday it had stopped testing its lead drug as a treatment for respiratory illness after it failed to meet the main goal in a late-stage trial, sending the company's shares down nearly 70%. 
Reuters: Health
ResTORbio Inc said on Friday it had stopped testing its lead drug as a treatment for respiratory illness after it failed to meet the main goal in a late-stage trial, sending the company's shares down nearly 70%.
Jazz Pharma's sleep disorder drug gets European panel backing
Jazz Pharma's sleep disorder drug gets European panel backing
Reuters: Health
Jazz Pharmaceuticals Plc's treatment for a form of sleep disorder has been recommended for approval in Europe by a panel of the European Medicines Agency (EMA), the regulator said on Friday. 
Reuters: Health
Jazz Pharmaceuticals Plc's treatment for a form of sleep disorder has been recommended for approval in Europe by a panel of the European Medicines Agency (EMA), the regulator said on Friday.
Robert F. Kennedy Jr. is the single leading source of anti-vax ads on Facebook
Robert F. Kennedy Jr. is the single leading source of anti-vax ads on Facebook
https://ift.tt/2OsByqv November 15, 2019 at 06:15PM https://ift.tt/1R552o9
 |
submitted by /u/mvea [link] [comments] |
In a surprising finding using the standard animal model of Down syndrome, scientists reversed the intellectual deficits, generally thought of as irreversible, with drugs that target the body’s response to cellular stresses, suggesting it may be possible to do the same in humans with Down syndrome.
In a surprising finding using the standard animal model of Down syndrome, scientists reversed the intellectual deficits, generally thought of as irreversible, with drugs that target the body’s response to cellular stresses, suggesting it may be possible to do the same in humans with Down syndrome.
https://ift.tt/32Q8myG November 15, 2019 at 06:06PM https://ift.tt/1R552o9
 |
submitted by /u/mvea [link] [comments] |
Subscribe to:
Posts (Atom)